TP53 and plasma cell myeloma: This agent was shown to be active against in vitro and in vivo wt p53 myeloma models through a p53-dependent program (Figure 1) including PUMA, Bax, p21, and Noxa, leading to cell cycle arrest and apoptosis (Figure 2).